Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Athanassios Argiris, Chun Xia Wang, Steve G. Whalen, Michael P. DiGiovanna

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: HER-2/neu and estrogen receptor (ER) are critical in the biology of breast carcinoma, and both are validated therapeutic targets. Extensive interactions between the signaling pathways of these receptors have been demonstrated. This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments. Experimental Design: ER-positive, HER-2/neu-overexpressing BT-474 human breast carcinoma cells were cultured in the presence of the anti-HER-2/neu therapeutic antibody trastuzumab (Herceptin), the antiestrogen tamoxifen, or both. The effects on cell growth, cell cycle distribution, clonogenicity, survival, and the level and activity of HER-2/neu were examined. Results: The combination of tamoxifen and Herceptin resulted in synergistic growth inhibition and enhancement of cell accumulation in the G 0-G1 phase of the cell cycle, with a decrease in cells in S phase. Clonogenicity was inhibited in the presence of each drug and more so by the combination, although prior exposure to drugs did not affect subsequent clonogenicity in drug-free media, and neither drug nor the combination induced apoptosis. Herceptin, but not tamoxifen, inhibited signaling by HER-2/neu. Conclusions: The combination of tamoxifen and Herceptin is formally demonstrated to result in synergistic growth inhibition and enhancement of G0-G1 cell cycle accumulation. In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)1409-1420
Number of pages12
JournalClinical Cancer Research
Volume10
Issue number4
DOIs
StatePublished - Feb 15 2004
Externally publishedYes

Fingerprint

Tamoxifen
Breast Neoplasms
Cell Cycle
Drug Combinations
Estrogen Receptors
Growth
ErbB-2 Receptor
Pharmaceutical Preparations
Estrogen Receptor beta
Estrogen Receptor Modulators
G1 Phase
Cytostatic Agents
S Phase
Cultured Cells
Research Design
Cell Culture Techniques
Trastuzumab
Apoptosis
Survival
Antibodies

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). / Argiris, Athanassios; Wang, Chun Xia; Whalen, Steve G.; DiGiovanna, Michael P.

In: Clinical Cancer Research, Vol. 10, No. 4, 15.02.2004, p. 1409-1420.

Research output: Contribution to journalArticle

Argiris, A, Wang, CX, Whalen, SG & DiGiovanna, MP 2004, 'Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)', Clinical Cancer Research, vol. 10, no. 4, pp. 1409-1420. https://doi.org/10.1158/1078-0432.CCR-1060-02
Argiris, Athanassios ; Wang, Chun Xia ; Whalen, Steve G. ; DiGiovanna, Michael P. / Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin). In: Clinical Cancer Research. 2004 ; Vol. 10, No. 4. pp. 1409-1420.
@article{655f23e2c98347df83ebb22c23c9e6cf,
title = "Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)",
abstract = "Purpose: HER-2/neu and estrogen receptor (ER) are critical in the biology of breast carcinoma, and both are validated therapeutic targets. Extensive interactions between the signaling pathways of these receptors have been demonstrated. This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments. Experimental Design: ER-positive, HER-2/neu-overexpressing BT-474 human breast carcinoma cells were cultured in the presence of the anti-HER-2/neu therapeutic antibody trastuzumab (Herceptin), the antiestrogen tamoxifen, or both. The effects on cell growth, cell cycle distribution, clonogenicity, survival, and the level and activity of HER-2/neu were examined. Results: The combination of tamoxifen and Herceptin resulted in synergistic growth inhibition and enhancement of cell accumulation in the G 0-G1 phase of the cell cycle, with a decrease in cells in S phase. Clonogenicity was inhibited in the presence of each drug and more so by the combination, although prior exposure to drugs did not affect subsequent clonogenicity in drug-free media, and neither drug nor the combination induced apoptosis. Herceptin, but not tamoxifen, inhibited signaling by HER-2/neu. Conclusions: The combination of tamoxifen and Herceptin is formally demonstrated to result in synergistic growth inhibition and enhancement of G0-G1 cell cycle accumulation. In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer.",
author = "Athanassios Argiris and Wang, {Chun Xia} and Whalen, {Steve G.} and DiGiovanna, {Michael P.}",
year = "2004",
month = "2",
day = "15",
doi = "10.1158/1078-0432.CCR-1060-02",
language = "English (US)",
volume = "10",
pages = "1409--1420",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

AU - Argiris, Athanassios

AU - Wang, Chun Xia

AU - Whalen, Steve G.

AU - DiGiovanna, Michael P.

PY - 2004/2/15

Y1 - 2004/2/15

N2 - Purpose: HER-2/neu and estrogen receptor (ER) are critical in the biology of breast carcinoma, and both are validated therapeutic targets. Extensive interactions between the signaling pathways of these receptors have been demonstrated. This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments. Experimental Design: ER-positive, HER-2/neu-overexpressing BT-474 human breast carcinoma cells were cultured in the presence of the anti-HER-2/neu therapeutic antibody trastuzumab (Herceptin), the antiestrogen tamoxifen, or both. The effects on cell growth, cell cycle distribution, clonogenicity, survival, and the level and activity of HER-2/neu were examined. Results: The combination of tamoxifen and Herceptin resulted in synergistic growth inhibition and enhancement of cell accumulation in the G 0-G1 phase of the cell cycle, with a decrease in cells in S phase. Clonogenicity was inhibited in the presence of each drug and more so by the combination, although prior exposure to drugs did not affect subsequent clonogenicity in drug-free media, and neither drug nor the combination induced apoptosis. Herceptin, but not tamoxifen, inhibited signaling by HER-2/neu. Conclusions: The combination of tamoxifen and Herceptin is formally demonstrated to result in synergistic growth inhibition and enhancement of G0-G1 cell cycle accumulation. In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer.

AB - Purpose: HER-2/neu and estrogen receptor (ER) are critical in the biology of breast carcinoma, and both are validated therapeutic targets. Extensive interactions between the signaling pathways of these receptors have been demonstrated. This suggests that targeting both receptors simultaneously may have a dramatic effect on the biology of breast cancer. This hypothesis was tested in cell culture experiments. Experimental Design: ER-positive, HER-2/neu-overexpressing BT-474 human breast carcinoma cells were cultured in the presence of the anti-HER-2/neu therapeutic antibody trastuzumab (Herceptin), the antiestrogen tamoxifen, or both. The effects on cell growth, cell cycle distribution, clonogenicity, survival, and the level and activity of HER-2/neu were examined. Results: The combination of tamoxifen and Herceptin resulted in synergistic growth inhibition and enhancement of cell accumulation in the G 0-G1 phase of the cell cycle, with a decrease in cells in S phase. Clonogenicity was inhibited in the presence of each drug and more so by the combination, although prior exposure to drugs did not affect subsequent clonogenicity in drug-free media, and neither drug nor the combination induced apoptosis. Herceptin, but not tamoxifen, inhibited signaling by HER-2/neu. Conclusions: The combination of tamoxifen and Herceptin is formally demonstrated to result in synergistic growth inhibition and enhancement of G0-G1 cell cycle accumulation. In vitro, the individual drugs or combination produces a cytostatic effect. These results suggest that combined inhibition of ER and HER-2/neu signaling may represent a powerful approach to the treatment of breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=1642406972&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642406972&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-1060-02

DO - 10.1158/1078-0432.CCR-1060-02

M3 - Article

C2 - 14977844

AN - SCOPUS:1642406972

VL - 10

SP - 1409

EP - 1420

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 4

ER -